C. Daniel Mullins

C. Daniel Mullins's AcademicInfluence.com Rankings

C. Daniel Mullins

Chemistry

#5049

World Rank

#6153

Historical Rank

chemistry Degrees

Download Badge

Chemistry

C. Daniel Mullins's Degrees

PhD Pharmaceutical Health Services Research University of Maryland, College Park
Masters Pharmaceutical Health Services Research University of Maryland, College Park
Bachelors Pharmacy University of Maryland, College Park

Why Is C. Daniel Mullins Influential?

(Suggest an Edit or Addition)

(See a Problem?)

C. Daniel Mullins's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. (2007) (616)
Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. (2007) (566)
Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. (2012) (397)
Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer (2014) (330)
Cost-of-illness studies : a review of current methods. (2006) (176)
Continuous patient engagement in comparative effectiveness research. (2012) (169)
Personalized Strategies to Activate and Empower Patients in Health Care and Reduce Health Disparities (2016) (127)
Health disparities: a barrier to high-quality care. (2005) (126)
Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. (2017) (123)
Barriers to self-management of diabetes: a qualitative study among low-income minority diabetics. (2014) (123)
Cost-of-Illness Studies (2012) (119)
The total economic burden of overactive bladder in the United States: a disease-specific approach. (2009) (115)
Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. (2017) (106)
Impact of patient involvement on clinical practice guideline development: a parallel group study (2018) (106)
Practice Management Guidelines for Prophylactic Antibiotic Use in Tube Thoracostomy for Traumatic Hemopneumothorax: the EAST Practice Management Guidelines Work Group. Eastern Association for Trauma. (2000) (101)
Dental visits to hospital emergency departments by adults receiving Medicaid: assessing their use. (2002) (94)
A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. (2014) (90)
Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. (1997) (88)
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. (2010) (86)
Patients' attitudes about living donor transplantation and living donor nephrectomy. (2003) (83)
Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0 (2017) (79)
Framework for enhancing clinical practice guidelines through continuous patient engagement (2016) (78)
Persistence, Switching, and Discontinuation Rates Among Patients Receiving Sertraline, Paroxetine, and Citalopram (2005) (75)
Budget impact analysis: review of the state of the art (2005) (73)
The development of direct-to-consumer prescription drug advertising regulation. (2002) (71)
Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia (2008) (70)
Patient-centeredness in the design of clinical trials. (2014) (70)
Cost-of-Illness Studies: An Updated Review of Current Methods (2015) (69)
Reasons for discharges against medical advice: a qualitative study (2010) (66)
Practice management guidelines for prophylactic antibiotic use in penetrating abdominal trauma: the EAST Practice Management Guidelines Work Group. (2000) (66)
Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. (2007) (64)
Healthcare Rationing by Proxy (2012) (62)
Effect of Age on Survival Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer (2009) (61)
Impact of the 2004 Food and Drug Administration Pediatric Suicidality Warning on Antidepressant and Psychotherapy Treatment for New-Onset Depression (2010) (60)
From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer (2012) (58)
Discontinuation rates of topical glaucoma medications in a managed care population. (2002) (57)
Do value thresholds for oncology drugs differ from nononcology drugs? (2015) (57)
Cervical cancer outcomes analysis: impact of age, race, and comorbid illness on hospitalizations for invasive carcinoma of the cervix. (2000) (54)
Dementia severity and the longitudinal costs of informal care in the Cache County population (2015) (52)
Uncertainty in assessing value of oncology treatments. (2010) (51)
Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol (2019) (50)
Recommendations for patient engagement in guideline development panels: A qualitative focus group study of guideline-naïve patients (2017) (50)
Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. (2005) (49)
Dysnatremia is a Predictor for Morbidity and Mortality in Hospitalized Patients with COVID-19 (2021) (49)
Exploring the relationship between Alzheimer's disease severity and longitudinal costs. (2012) (48)
Exploring Donors' and Recipients' Attitudes about Living Donor Kidney Transplantation (2003) (48)
The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer (2014) (47)
Emerging standardization in pharmacoeconomics. (1998) (45)
A survey of nephrologists' views on preemptive transplantation. (2008) (45)
Exploring donors' and recipients' attitudes about living donor kidney transplantation. (2003) (44)
Engaging hard-to-reach patients in patient-centered outcomes research. (2013) (43)
The economic impact of laparoscopic living-donor nephrectomy on kidney transplantation (2003) (43)
White paper: value of specialty certification in pharmacy. (2004) (43)
Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer (2014) (42)
Disparities in Access to Essential New Prescription Drugs between Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanic Whites (2006) (42)
A Sustainable Strategy to Prevent Misuse of Antibiotics for Acute Respiratory Infections (2012) (39)
Healthcare Rationing by Proxy Cost-Effectiveness Analysis and the Misuse of the $50 000 Threshold in the US (2009) (39)
Using community-based participatory research in patient-centered outcomes research to address health disparities in under-represented communities. (2015) (38)
Disparity implications of Medicare eligibility criteria for medication therapy management services. (2010) (38)
Comparative and Cost Effectiveness of Treatment Modalities for Hepatocellular Carcinoma in SEER-Medicare (2013) (36)
The Direct Medical Costs of α1-Antitrypsin Deficiency* (2001) (36)
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. (2020) (35)
Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review. (2013) (35)
Hospital admissions associated with nontraumatic dental emergencies in a Medicaid population. (2003) (34)
Generating Evidence for Comparative Effectiveness Research Using More Pragmatic Randomized Controlled Trials (2012) (34)
Cost-effectiveness of a motivational intervention to reduce rapid repeated childbearing in high-risk adolescent mothers: a rebirth of economic and policy considerations. (2010) (33)
Transitioning from learning healthcare systems to learning health care communities. (2018) (33)
Trends in Disparities in Receipt of Adjuvant Therapy for Elderly Stage III Colon Cancer Patients: The Role of the Medical Oncologist Evaluation (2009) (33)
Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance. (2008) (32)
Improving transparency to build trust in real‐world secondary data studies for hypothesis testing—Why, what, and how: recommendations and a road map from the real‐world evidence transparency initiative (2020) (32)
Practice Management Guidelines for Prophylactic Antibiotic Use in Tube Thoracostomy for Traumatic Hemopneumothorax: The EAST Practice management Guidelines Work Group (2000) (32)
Stakeholder engagement in patient-centered outcomes research: high-touch or high-tech? (2014) (32)
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome (2011) (31)
The Baltimore Partnership to Educate and Achieve Control of Hypertension (The BPTEACH Trial): A Randomized Trial of the Effect of Education on Improving Blood Pressure Control in a Largely African American Population (2011) (31)
Patient engagement and shared decision-making: What do they look like in neurology practice? (2016) (31)
Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer. (2010) (31)
Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in SEER-Medicare (2015) (31)
Effects of a Medicaid prior authorization policy for pregabalin. (2009) (30)
Short-Term Impact of an Educational Program Promoting Live Donor Kidney Transplantation in Dialysis Centers (2008) (30)
Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. (2015) (30)
Drug therapy persistence and stroke recurrence. (2006) (30)
Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. (2005) (29)
Indirect cost of HIV infection in England. (2000) (29)
Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. (2010) (29)
Factors associated with hospitalization costs for patients with community-acquired pneumonia. (2003) (28)
Variability and growth in spending for outpatient specialty pharmaceuticals. (2005) (28)
Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. (2003) (27)
Health care cost and utilization project analysis of comorbid illness and complications for patients undergoing hysterectomy for endometrial carcinoma (2001) (26)
New Diagnosis of Hypertension among Celecoxib and Nonselective NSAID Users: A Population-Based Cohort Study (2007) (26)
A Medicaid population's use of physicians' offices for dental problems. (2003) (26)
The impact of pipeline drugs on drug spending growth. (2001) (26)
Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study (2013) (26)
Center effects in anemia management of dialysis patients. (2007) (26)
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. (2010) (26)
Health disparities in staging of SEER-medicare prostate cancer patients in the United States. (2010) (26)
Major Components of the Direct Medical Costs of α1-Antitrypsin Deficiency (2003) (25)
Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO. (1999) (25)
Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study (2015) (25)
PHARMACEUTICAL CARE INTERVENTION DOCUMENTATION PROGRAM AND RELATED COST SAVINGS AT A UNIVERSITY HOSPITAL (1999) (25)
Patterns and Correlates of Linkage to Appropriate HIV Care After HIV Diagnosis in the US Medicaid Population (2013) (25)
Comparative Effectiveness of Different Chemotherapeutic Regimens on Survival of People Aged 66 and Older with Stage III Colon Cancer: A “Real World” Analysis Using Surveillance, Epidemiology, and End Results–Medicare Data (2011) (25)
Rating of Included Trials on the Efficacy-Effectiveness Spectrum: development of a new tool for systematic reviews. (2017) (24)
Value Assessment at the Point of Care: Incorporating Patient Values throughout Care Delivery and a Draft Taxonomy of Patient Values. (2017) (24)
The Breathmobile program: a good investment for underserved children with asthma. (2010) (23)
Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases (2011) (23)
Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods (2015) (23)
Perspectives on electronic medical records adoption: electronic medical records (EMR) in outcomes research (2010) (23)
Chemotherapy Treatment and Survival in Older Women with Estrogen Receptor–Negative Metastatic Breast Cancer: A Population‐Based Analysis (2011) (22)
Evaluating the Cost-Effectiveness of Hydrogel Rectal Spacer in Prostate Cancer Radiation Therapy. (2019) (22)
"Ten commandments" for conducting comparative effectiveness research using "real-world data". (2011) (21)
An Economic Evaluation of Triptan Products for Migraine (2005) (21)
Impact of an educational intervention for secondary prevention of myocardial infarction on Medicaid drug use and cost. (2004) (20)
Economic disparities in treatment costs among ambulatory Medicaid cancer patients. (2004) (20)
Patient preferences for venous thromboembolism prophylaxis after injury: a discrete choice experiment (2017) (20)
Comparison of first refill rates among users of sertraline, paroxetine, and citalopram. (2006) (20)
A qualitative study to identify reasons for discharges against medical advice in the cardiovascular setting (2012) (20)
Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer. (2009) (20)
Medication access through patient assistance programs. (2006) (20)
Skeletal-related events and mortality among older men with advanced prostate cancer. (2014) (19)
Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using Surveillance, Epidemiology and End Results (SEER)‐Medicare data (2012) (19)
Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancer. (2012) (19)
Using Bayesian Adaptive Trial Designs for Comparative Effectiveness Research: A Virtual Trial Execution. (2016) (19)
The direct medical costs of alpha(1)-antitrypsin deficiency. (2001) (19)
Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report. (2020) (18)
Effect of initial ziprasidone dose on treatment persistence in schizophrenia (2006) (18)
Major components of the direct medical costs of alpha1-antitrypsin deficiency. (2003) (18)
Health disparities research--a model for conducting research on cancer disparities: characterization and reduction. (2002) (18)
Understanding the experience of living with non-small-cell lung cancer (NSCLC): a qualitative study. (2014) (18)
Racial Differences in Hospital Discharge Disposition among Stroke Patients in Maryland (2007) (17)
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations (2022) (17)
The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case–control study (2010) (17)
Hospital Center Effect for Laparoscopic Colectomy Among Elderly Stage I-III Colon Cancer Patients (2013) (17)
A Systematic Review of Entrepreneurship in Pharmacy Practice and Education (2019) (16)
Early assessment of the 10-step patient engagement framework for patient-centred outcomes research studies: the first three steps (2017) (16)
New perspectives on overactive bladder: quality of life impact, medication persistency, and treatment costs. (2005) (16)
Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. (2008) (16)
Understanding preferences for type 2 diabetes mellitus self-management support through a patient-centered approach: a 2-phase mixed-methods study (2016) (16)
Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. (2005) (16)
The potential impact of comparative effectiveness research on the health of minority populations. (2010) (16)
Medicaid Coverage and Utilization of Adult Dental Services (2004) (16)
Selective cyclooxygenase-2 inhibition and cardiovascular effects: An observational study of a Medicaid population (2005) (16)
Understanding heterogeneity of treatment effect in prostate cancer (2015) (16)
Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible? (2002) (15)
What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism (2019) (15)
Haemodialysis patients' readiness to pursue live donor kidney transplantation. (2008) (15)
Comparative and cost‐effectiveness of oxaliplatin‐based or irinotecan‐based regimens compared with 5‐fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients (2012) (15)
Participation and consultation engagement strategies have complementary roles: A case study of patient and public involvement in clinical practice guideline development (2019) (15)
Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis (2019) (15)
Lessons learned from community-based minority health care serving system participation in an NIH clinical trial. (2011) (15)
Incorporating observational data into the formulary decision-making process--summary of a roundtable discussion. (2008) (14)
Development of a guidance for including patient-reported outcomes (PROs) in post-approval clinical trials of oncology drugs for comparative effectiveness research (CER). (2011) (14)
College students' perceived benefit-to-risk tradeoffs for nonmedical use of prescription stimulants: Implications for intervention designs. (2018) (14)
Age-related racial disparities in prostate cancer patients: A systematic review (2017) (14)
Resources and use of the intensive care unit in patients who undergo surgery for ovarian carcinoma (2002) (14)
Health plans' strategies for managing outpatient specialty pharmaceuticals. (2006) (14)
Tree-based Claims Algorithm for Measuring Pretreatment Quality of Care in Medicare Disabled Hepatitis C Patients (2017) (14)
Perception of Barriers to the Diagnosis and Receipt of Treatment for Neuropsychiatric Disturbances After Traumatic Brain Injury. (2017) (14)
What are outcomes? (1996) (14)
Future of Patients in Healthcare Evaluation: The Patient-Informed Reference Case. (2019) (14)
Comparisons of Hypertension-Related Costs from Multinational Clinical Studies (2012) (14)
Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs health care system. (2008) (14)
Study protocol testing toolkit versus usual care for implementation of screening, brief intervention, referral to treatment in hospitals: a phased cluster randomized approach (2018) (13)
Disparities in prevalence rates for lung, colorectal, breast, and prostate cancers in Medicaid. (2004) (13)
Incidence versus prevalence modeling in pharmacoeconomics (2002) (13)
Pharmacy Benefit Management (2002) (13)
Rifampicin for Continuation Phase Tuberculosis Treatment in Uganda: A Cost-Effectiveness Analysis (2012) (13)
Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer. (2012) (13)
BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles (2016) (13)
Medical Expenditure Panel Survey: a valuable database for studying racial and ethnic disparities in prescription drug use. (2008) (12)
A qualitative evaluation of a citywide Community Health Partnership program. (2012) (12)
The value of atorvastatin over the product life cycle in the United States. (2011) (12)
Racial disparities in urologist visits among elderly men with prostate cancer: A cohort analysis of patient‐related and county of residence‐related factors (2014) (12)
Prescribing trends and drug budget impact of the ARBs in the UK. (2009) (12)
Discriminatory power of a 25-item distress screening tool: a cross-sectional survey of 251 cancer survivors (2014) (12)
Multispecialist Care and Mortality in Hepatocellular Carcinoma (2015) (12)
What are outcomes (1996) (11)
Recommendations for the design of Phase 3 pharmaceutical trials that are more informative for patients, clinicians, and payers. (2013) (11)
Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings. (2012) (11)
Readmissions After Unauthorized Discharges in the Cardiovascular Setting (2011) (11)
Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making. (2002) (11)
Costs of Medical Care Among Augmentation Therapy Users and Non-Users with Alpha-1 Antitrypsin Deficiency in the United States. (2018) (11)
Short-term impact of an educational program promoting live donor kidney transplantation in dialysis centers. (2008) (10)
Resource utilization for patients undergoing hysterectomy with or without lymph node dissection for endometrial cancer. (2002) (10)
Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer. (2011) (10)
Emerging Good Practices for Transforming Value Assessment: Patients' Voices, Patients' Values. (2018) (10)
PEER-REVIEWED JOURNAL EDITORS’ VIEWS ON REAL-WORLD EVIDENCE (2018) (10)
Double counting and the reporting of cost per event avoided. (2006) (10)
Principles of economics crucial to pharmacy students' understanding of the prescription drug market. (2008) (10)
Continuous patient engagement in cardiovascular disease clinical comparative effectiveness research (2016) (9)
Criteria to Request Pharmacoeconomic Data and Data Sources for Hospital Formulary Decisions (2001) (9)
Selection of clinical, patient-reported, and economic end points in acute exacerbation of chronic bronchitis. (2001) (9)
“I’m a Little More Trusting”: Components of Trustworthiness in the Decision to Participate in Genomics Research for African Americans (2020) (9)
The use of health services among elderly patients with stage IV prostate cancer in the initial period following diagnosis. (2014) (9)
Patients’ early engagement in research proposal development (PEER-PD): patients guiding the proposal writing (2019) (9)
The economic burden associated with SSRI treatment failure in a managed care population (2008) (9)
Site engagement for multi-site clinical trials (2020) (8)
If patients are the true north, patient-centeredness should guide research (2018) (8)
Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis (2017) (8)
Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index. (2007) (8)
Policy implications of drug importation. (2007) (8)
PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients (2021) (8)
Pulmonary artery intimal injury associated with blunt trauma (2009) (8)
Six ways to foster community-engaged research during times of societal crises (2020) (7)
Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids (2018) (7)
Economic evaluations of sunitinib versus interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC) (2007) (7)
Economic Analysis of Triptan Therapy for Acute Migraine: A Medicaid Perspective (2007) (7)
What works when: mapping patient and stakeholder engagement methods along the ten-step continuum framework. (2021) (7)
Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers, Peter J. Neumann (Ed.). Oxford University Press Oxford, U.K. (2004), 224, £19.99 ISBN 0-19-517186-1 (2006) (7)
Clinic visits and prescribing patterns among veterans affairs maryland health care system dementia patients (2010) (7)
Sequential Therapies and the Cost-Effectiveness of Treating Metastatic Colon Cancer Patients. (2016) (7)
Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer. (2016) (7)
Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease (2017) (7)
Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients (2013) (7)
Practice Management Guidelines for Prophylactic Antibiotic Use in Penetrating Abdominal Trauma: The EAST Practice Management Guidelines Work Group (2000) (7)
Prevalence and risk of skeletal complications and use of radiation therapy in elderly women diagnosed with metastatic breast cancer (2018) (7)
A framework for pharmacist-assisted medication adherence in hard-to-reach patients. (2015) (6)
Therapy (Tx) of locally advanced (LA) NSCLC in the elderly: Analysis of 6,325 patients from Surveillance, Epidemiology and End Results (SEER)-Medicare (2008) (6)
HP6: THE IMPACT OF PIPELINE DRUGS ON UNITED STATES DRUG EXPENDITURE GROWTH TRENDS (2001) (6)
Patient Stakeholder Versus Physician Preferences Regarding Amyloid PET Testing (2019) (6)
Cost-Effectiveness of Second-Line Chemotherapy/Biologics among Elderly Metastatic Colon Cancer Patients (2014) (6)
Does Earlier Headache Response Equate to Earlier Return to Functioning in Patients Suffering from Migraine? (2006) (6)
Advancing community-engaged research: increasing trustworthiness within community-academic partnerships. (2020) (6)
Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients (2014) (5)
Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. (2011) (5)
Bone metastasis (BM) based on SEER registry versus Medicare claims among metastatic prostate cancer (PCa) patients (pts) in SEER-Medicare. (2012) (5)
Chemotherapy (C) and survival among 21,441 elderly (E) patients (pts) with advanced (adv) NSCLC: Analysis of SEER-Medicare claim data 1997-2002 (2008) (5)
Recommendations for Good Procedural Practices for Real-World Data Studies of Treatment Effectiveness and/or Comparative Effectiveness Designed to Inform Health Care Decisions: Report of the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making (2017) (5)
How Do US Health Care Payers React to and Use Pharmacoeconomic Information? (2011) (5)
Societal implications of the pharmacoeconomics of α1-antitrypsin deficiency (2002) (5)
Pharmapreneur – Defining a Framework for Entrepreneurship in Pharmacy Education (2019) (5)
Pragmatic patient engagement in designing pragmatic oncology clinical trials. (2021) (5)
A Simplified Approach to Teaching Markov Models (1996) (5)
Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter? (2016) (5)
An Approach to Adapting a Community-Based Cancer Control Intervention to Organizational Context (2020) (5)
Developing a collaborative study protocol for combining payer-specific data and clinical trials for CER. (2011) (5)
Association of Postoperative Infections After Fractures With Long-term Income Among Adults (2021) (5)
KRAS tests utilizations, biologics uptakes, and disparities in access by demographic groups among metastatic colon cancer patients. (2015) (4)
Engaging Stakeholders to Optimize Sleep Disorders' Management in the U.S. Military: A Qualitative Analysis. (2021) (4)
Intervention for decreasing excessive acetaminophen use in Pennsylvania Medicaid recipients. (2004) (4)
Diabetes control through an educational intervention. (2014) (4)
Strategies to Prevent MRSA Transmission in Community-Based Nursing Homes: A Cost Analysis (2016) (4)
Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials (2021) (4)
Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone (2017) (4)
Combining the Principles of Epidemiology and Economics 1 (1994) (4)
Specialist visits and initiation of cancer-directed treatment among a large cohort of men diagnosed with prostate cancer. (2017) (3)
Prescription drug spending trends for the privately insured in Maryland, 2000-2001. (2004) (3)
Pharmacists' Assessment of Facets of Health Literacy in Pharmacy Practice Settings (2011) (3)
Patient and Provider Acceptability of a Patient Preauthorized Concealed Opioid Reduction. (2021) (3)
Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools. (2019) (3)
Pragmatic randomized trial evaluating pre-operative aqueous antiseptic skin solution in open fractures (Aqueous-PREP): the feasibility of a cluster randomized crossover study (2021) (3)
Comparisons of changes over time in per capita health expenditures across racial and ethnic groups (2010) (3)
Health care cost of analgesic use in hypertensive patients. (2004) (3)
Cost effectiveness of kinetic therapy in preventing nosocomial lower respiratory tract infections in patients suffering from trauma. (2002) (3)
Survival benefit associated with the number of chemotherapy/biologic treatment lines in 5,129 elderly metastatic colon cancer patients. (2013) (3)
Evaluation of Tigecycline Efficacy and Post-Discharge Outcomes in a Clinical Practice Population with Complicated Intra-Abdominal Infection: A Propensity Score–Matched Analysis (2016) (3)
Overview of Cancer Economics (1999) (3)
Effect of age on survival benefit of adjuvant chemotherapy in elderly stage III colon cancer patients: a population-based analysis (2008) (3)
Rising copayments and the kinked demand curve (2003) (3)
Veteran engagement in opioid tapering research: a mission to optimize pain management (2021) (3)
Epidemiology of public transportation use among older adults in the United States (2022) (3)
Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415 (2021) (3)
Aqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial (2022) (3)
A LITERATURE REVIEW OF FACTORS AFFECTING PRICE AND COMPETITION IN THE GLOBAL PHARMACEUTICAL MARKET (2016) (3)
Evolving Use of Real-World Evidence for Devices: Good for Patients, Good for Policy Makers. (2019) (3)
Health-related quality of life as a potential predictor in chronic obstructive lung disease patients (2007) (3)
The emerging relevance of heterogeneity of treatment effect in clinical care: a study using stage IV prostate cancer as a model. (2013) (3)
Comparative analysis of second and subsequent chemotherapy lines on short- and long-term survival of elderly Medicare metastatic colon cancer patients. (2013) (2)
Is there evidence of diminishing disparities in treatment (tx) with adjuvant (adj) chemotherapy (Ch) among elderly (E) stage 3 colon cancer (CC) patients (pts)? An analysis of 8,374 pts from SEER-Medicare data (2008) (2)
Low-Risk Papillary Thyroid Cancer: Treatment De-Escalation and Cost Implications. (2022) (2)
Active Duty Service Members, Primary Managers, and Administrators' Perspectives on a Novel Sleep Telehealth Management Platform in the U.S. Military Healthcare System. (2022) (2)
Heterogeneity of treatment effects (HTE) in stage IV prostate cancer (S4PC). (2012) (2)
Threshold denial rates in prior authorization prescription programs (2004) (2)
PCVD14: USE OF CONFIDENCE INTERVALS TO ESTIMATE THE COST-EFFECTIVENESS OF ABCIXIMAB (1999) (2)
Pharmaceutical Market Impact of the Early 1990's Health Care Debate (2001) (2)
Applications of Pharmacoeconomics for Managed Care Pharmacy (2015) (2)
Value of Propensity Score Matching for Equalizing Comparator Groups in Observational Database Studies: A Case Study in Anti-infectives. (2016) (2)
The need to address uncertainty and heterogeneity of treatment effect in clinical studies. (2010) (2)
Impact of the fourth hurdle on the international pharmaceutical industry (2003) (2)
New perspectives on overactive bladder and its treatment. Introduction. (2009) (2)
Continuous patient engagement in comparative effectiveness research (CER): An application in cardiovascular disease (CVD) (2014) (2)
The Role of Health Economics and Outcomes Research in Addressing Coronavirus Disease 2019 (COVID-19) (2020) (2)
Oncology Pharmacy Management and the Evolving Role of Managed Care: Recommendations for a Changing Environment with a Focus on Multiple Myeloma (2015) (2)
Querying stakeholders to inform comparative effectiveness research. (2017) (2)
Patient and stakeholder engagement learnings: PREP-IT as a case study. (2021) (2)
The peer-review process: gifts of time. (2005) (2)
The increasing use of the internet for obtaining medical information. (2004) (2)
The Affordable Care Act, health care reform, prescription drug formularies and utilization management tools. (2015) (2)
Burden and Timing of First and Subsequent Skeletal Related Events (SRES) in United States Elderly Men with Metastatic Prostate Cancer (MPC) (2014) (2)
Limitations and Challenges of Conducting Budget Impact Analyses in Rare Diseases: A Case Study of Alpha-1 Antitrypsin Deficiency. (2020) (2)
Variation in the Length of Radiation Therapy Among Men Diagnosed With Incident Metastatic Prostate Cancer (2013) (2)
Patient and Stakeholder Engagement in Designing Pragmatic Clinical Trials (2017) (2)
Risk of Heart Failure with the Use of Thiazolidinediones within a Medicaid Population (2005) (2)
Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States (2019) (2)
Treat Now or Treat Later: Comparative Effectiveness of Adjuvant Therapy in Resected Stage IIIA Melanoma. (2022) (1)
The impact of COVID-19 restrictions on participant enrollment in the PREPARE trial (2022) (1)
Total thyroidectomy is more cost-effective than radioactive iodine as an alternative to antithyroid medication for Graves' disease. (2022) (1)
The new administration and Medicare reform. (2001) (1)
Population Health and the Patient (2015) (1)
Difficulties in applying clinical trial information to the practice setting: case of a high-cost drug. (1998) (1)
PCV15 NEW DIAGNOSIS OF HYPERTENSION AMONG CELECOXIB AND NON-SELECTIVE NSAID USERS:A POPULATION-BASED COHORT STUDY (2007) (1)
The visibility and divisibility of quality-adjusted life-years. (2005) (1)
Access to pharmaceuticals in the post‐Medicare Part D era (2010) (1)
PCV18 COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PRAVASTATIN, AND SIMVASTATIN (2004) (1)
Prevalence of fractures among men with stage IV prostate cancer (S4PC). (2014) (1)
PIN17 COST-EFFECTIVENESS MODELING OF TREATMENT APPROACHES TO HEPATITIS C: A MANAGED CARE PERSPECTIVE (2004) (1)
PMH5 INFLUENCE OF PSYCHIATRIC COMORBIDITY AND POLYPHARMACY ON HOSPITALIZATION AND EXPENDITURES AMONG SECOND GENERATION ANTIPSYCHOTIC USERS WITH METABOLIC SYNDROME (2010) (1)
Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What? (2017) (1)
Characteristics of triple-negative metastatic breast cancer among older adults: A population-based analysis. (2010) (1)
PMH66 COMPARISON OF FIRST REFILL RATES AMONG BRANDED SSRI USERS (2004) (1)
PCN31 DIRECT MEDICAL COSTS OF ELDERLY PATIENTS WITH STAGE III COLON CANCER DURING FIRST-LINE VERSUS SECOND-LINE CHEMOTHERAPY (2011) (1)
Gastrointestinal tumors, colorectal (2012) (1)
Physician prescribing and the hippocratic oath. (2005) (1)
Moving from General Predictors to Patient-Specific Indicators of Nonadherence (2008) (1)
It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction. (2011) (1)
Increasing utilization of endoscopic local excision for early-stage gastric cancers in the United States. (2022) (1)
Which orthopaedic trauma patients are likely to refuse to participate in a clinical trial? A latent class analysis (2019) (1)
Multispecialty care among hepatocellular carcinoma patients in SEER-Medicare. (2012) (1)
Cost Analysis Of Skeletal Related Events Among Elderly Men With Stage Iv Metastatic Prostate Cancer In Seer-Medicare (2013) (1)
Patient-Centric Structural Determinants of Adherence Rates Among Asthma Populations: Exploring the Potential of Patient Activation and Encouragement Tool TRUSTR to Improve Adherence (2020) (1)
Patient copayments and patient-reported outcomes (2002) (1)
Characteristics of stage III and IV M0 prostate cancer (PCa) patients in SEER-Medicare who develop bone metastasis (BM) following diagnosis. (2012) (1)
Who receives chemotherapy: An analysis of stage IV prostate cancer (PCa) patients in SEER-Medicare. (2010) (1)
The role of geography in health care dissemination (2007) (1)
The Use Of Transarterial Chemoembolization For Treating Hepatocellular Carcinoma In The Seer-Medicare Population (2013) (1)
Longitudinal versus Cross-Sectional Methodology for Estimating the Economic Burden of Breast Cancer (2012) (1)
PG13 MAJOR GI EVENTS AMONG ELDERLY CHRONIC USERS OF COX-2SAND NON-SELECTIVE NSAIDS, WITH/WITHOUT ASPIRIN (2006) (1)
Impact of Food and Drug Administration (FDA) paediatric antidepressant warnings on stock prices of pharmaceutical manufacturers (2010) (1)
Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guideline (GL) drug therapy recommendations for metastatic breast cancer: An analysis from the commercial managed care claims database PharMetrics (PM). (2010) (1)
Applying Oncology Formulary and Benefit Design Innovations to the Management of Multiple Myeloma in the Managed Care Setting (2015) (1)
Supply and demand in the decision-making process of pharmaceutical consumers: The starbucks versus dunkin' donuts dilemma (2009) (1)
Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. (2011) (1)
Definition of end-of-life period and Quality Benchmarks in Terminal Cancer Care: a Literature Review (2015) (1)
Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C (2015) (1)
A pragmatic randomized trial evaluating pre-operative aqueous antiseptic skin solutions in open fractures (Aqueous-PREP): statistical analysis plan (2022) (1)
Tree-based Claims Algorithm for Measuring Pretreatment Quality of Care in Medicare Disabled Hepatitis C Patients. (2015) (1)
Comparative analysis of treatments, utilization, and survival benefit in HCC patients: A real-world analysis of SEER Medicare. (2012) (1)
Correction to: Cluster identification, selection, and description in Cluster randomized crossover trials: the PREP-IT trials (2020) (1)
Cost-Effectiveness Of Grazoprevir / Elbasvir In Patients With Chronic Hepatitis C Virus (2016) (1)
Cluster-randomized trial comparing organizationally tailored versus standard approach for integrating an evidence-based cancer control intervention into African American churches. (2021) (1)
Similar values, different expectations: How do patients and providers view ‘health’ and perceive the healthcare experience? (2022) (1)
PIN56 Rehospitalization and Costs Among Patients Treated With Linezolid Versus Vancomycin Following Hospitalization for Pneumonia in the Real-World Setting (2012) (1)
Cost Effectiveness of Abciximab During Routine Medical Practice (2000) (1)
The impact of comorbidity on costs and effects of second-line treatment among elderly metastatic colon cancer patients. (2014) (1)
Research is needed on the difficult‐to‐cure population of hepatitis C virus patients with disability (2015) (1)
Physician referral patterns among men with advanced prostate cancer. (2014) (1)
Treatment Modalities For Hepatocellular Carcinoma: Cumulative Expenditures And Survival In Seer-Medicare (2013) (1)
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. (2022) (1)
The impact of clinical therapies (2003) (1)
Discriminatory power of a 25-item distress screening tool CancerSupport Source: A cross-sectional study of 251 cancer survivors. (2013) (1)
Are Communities Willing to Transition Into Learning Health Care Communities? A Community-Based Participatory Evaluation of Stakeholders’ Receptivity (2021) (1)
Affordable versus acceptable drug prices (2002) (1)
Pharmaceutical Restrictions (2001) (1)
How does dementia severity affect the costs of dementia care? (2013) (1)
PCN43 INITIAL COSTS OF TREATMENT AMONG STAGE IV PROSTATE CANCER (PCA) CHEMOTHERAPY PATIENTS IN SEER-MEDICARE (2010) (1)
Data Gathering: Early and Often (2007) (1)
DO JOURNAL EDITORS PERCEIVE REAL-WORLD EVIDENCE AS VALUABLE? (2016) (1)
PCN62 FIRST YEAR COST EXPENDITURES ASSOCIATED WITH HEAD AND NECK CANCER DIAGNOSIS IN THE U.S. MANAGED CARE POPULATION (2009) (1)
PCN106 Development of a Guidance for Including Patient-Reported Outcomes (PROs) in Late-Phase Adult Clinical Trials of Oncology Drugs for Comparative Effectiveness Research (CER) (2012) (1)
Sound public health policy: Focusing on saving the most lives possible. (2005) (0)
PRM174 The Need to Conduct Future Research on the Benefit of the Prostate Specific Antigen Screening Test Using the Value of Information Framework (2012) (0)
Prostate cancer (PC) follow-up and treatment by race in an equal access health system: A pilot study. (2013) (0)
Medical Costs of Alpha-1 Antitrypsin Deficiency: Evidence From Real-World Claims Data (2017) (0)
PCN6: CAN ICD-9 CODES BE USED AS A PROXY FOR DISEASE STAGING IN ECONOMIC EVALUATIONS? (2001) (0)
Understanding Caregiver Preferences for Treating Children with Intellectual and Cognitive Disabilities and a Mental Illness (2019) (0)
The authors reply ... Formulary decision-making should rely on the best available evidence (2006) (0)
PCN60 COST-EFFECTIVENESS OF OXALIPLATIN AND IRINOTECAN BASED COMBINATION THERAPY COMPARED WITH 5FU/LV FOR THE TREATMENT OF US ELDERLY ADVANCED COLON CANCER PATIENTS (2010) (0)
Skeletal-Related Events And Mortality Among Seer-Medicare Patients With Metastatic Prostate Cancer: The Implications Of Measurement Approach (2013) (0)
PMS30 ADHERENCE TO DULOXETINE AND HOSPITAL UTILIZATION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND CHRONIC PAIN (2010) (0)
Does first-line treatment impact the cost-effectiveness of second-line treatment for elderly metastatic colon cancer patients? (2014) (0)
Real-world treatment patterns and the uptake of biologics in elderly medicare patients with metastatic colon cancer. (2015) (0)
Comparative effectiveness of adjuvant oxaliplatin and irinotecan-based chemotherapy regimens among elderly stage III colon cancer patients completing 12 cycles. (2010) (0)
Recommendations for designing comparative effectiveness studies in oncology. (2011) (0)
PCN34 Descriptive Costs of Chemotherapy Treatment for Stage 3 and Stage 4 Colon Cancer (2012) (0)
The impact of docetaxel (D) in an older population of patients with advanced prostate cancer (PC): A simulation study using TAX327 and SEER Medicare data. (2009) (0)
Disparities and trends in prostate cancer staging over time (2008) (0)
PCR39 Patient and Caregiver Diversity in FDA Patient Engagement Activities and CBER-Regulated Therapeutics: A Review of the Literature (2022) (0)
DB4 ECONOMIC EVALUATION OF THIAZOLIDINEDIONES AS ADD-ON THERAPY FOR TREATMENT OF TYPE 2 DIABETIC PATIENTS IN THE TAIWANESE NATIONAL HEALTH INSURANCE SYSTEM (2010) (0)
PDB63 THE UTILIZATION OF ROSIGLITAZONE AND PIOGLITAZONE AFTER THE CARDIOVASCULAR RISK-WARNINGS: WAS THERE A DIFFERENTIAL EFFECT? (2009) (0)
A LITERATURE REVIEW OF STUDY DESIGN ELEMENTS IN COST-EFFECTIVENESS ANALYSES (2016) (0)
Use of biologics in addition to chemotherapy in the treatment of elderly Medicare patients with stage IV metastatic colon cancer. (2013) (0)
792 Hospital Center Effect for Laparoscopic Colectomy Among Elderly Stage I-III Colon Cancer Patients (2013) (0)
PCN66 COST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY AMONG U.S. BREAST CANCER PATIENTS (2009) (0)
Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guidelines (GL) for imaging work-up of patients with metastatic breast cancer: An analysis from the commercial managed care claims PharMetrics (PM) and SEER/Medicare (SM) databases. (2010) (0)
Clinical Decision Support At Time Of Prescribing To Decrease Inappropriate Antibiotics Prescribing For Treatment Of Acute Respiratory Infections (2010) (0)
PSR6 STROKE RECURRENCE AND PERSISTENCE ON DRUG THERAPY IN A MEDICAID POPULATION (2005) (0)
PMH65 SECOND SSRIS SWITCHING AND DISCONTINUATION AFTER FLUOXETINE INITIAL THERAPY (2004) (0)
Introduction: Economics of the Pharmaceutical Industry: Essays in Honor of Henry G. Grabowski (2011) (0)
PMH33 FACTORS INFLUENCING ZIPRASIDONE PRESCRIBED DOSES AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA (2005) (0)
Physician visits and the timing of skeletal-related events among men newly diagnosed with metastatic prostate cancer: A cohort analysis. (2018) (0)
PMD21 The Association of Major Adverse LIMB Events and Combination Stent and Atherectomy in Patients Undergoing Revascularization for Lower Extremity Peripheral Artery Disease (2021) (0)
Abstract P204: Reasons for Unauthorized Discharges Among Patients With Cardiovascular Disease: A Qualitative Study (2011) (0)
Incremental cost (IC) analysis of skeletal related events (SREs) among elderly men with stage IV metastatic (M1) prostate cancer (PCa). (2013) (0)
Frequency of second- and third-line treatment among elderly Medicare stage IV colon cancer patients. (2012) (0)
Sociodemographic factors impacting clinical trial enrollment and outcomes in stage III non-small cell lung cancer (NSCLC). (2014) (0)
Patterns of Psychotropic Medication Use among Individuals with Traumatic Brain Injury. (2019) (0)
An algorithm to identify delivery of palliative radiation therapy using health care claims data: A proof of concept application of data visualization tools in the prostate cancer (PCa) setting. (2014) (0)
PCV81 ASSESSING THE IMPACT OF INCORPORATING PATIENT KNOWLEDGE AND BELIEFS INTO ANTICOAGULATION THERAPY MANAGEMENT SERVICES (2008) (0)
College Students' Preferences for Components of a Campus-Sponsored Program to Reduce Nonmedical Use of Prescription Stimulants (2018) (0)
Predictors and prognostic implication of pathologic fracture (PF), spinal cord compression (SCC), and bone surgery (BS) following diagnosis of metastatic prostate cancer (PCa). (2013) (0)
Visit and treatment patterns over time among elderly patients (pts) with M1 prostate cancer (PC): An analysis using SEER-Medicare. (2009) (0)
PCN60 COSTS OF CARE FOR ELDERLY METASTATIC PROSTATE CANCER PATIENTS OVER TIME (2009) (0)
PCV51 THE VALUE OF ATORVASTATIN OVER THE PRODUCT LIFE CYCLE (2011) (0)
S1: IMPACT OF COMMUNITY-ACQUIRED PNEUMONIA TREATMENT GUIDELINES ON LENGTH OF STAY AND COST (2000) (0)
PHP23 EFFECT OF INSURANCE TYPE ON HEALTH PLANS' SPENDING ON SPECIALTY PHARMACEUTICALS: AN EMPIRICAL ANALYSIS (2006) (0)
ELICITING PATIENT PREFERENCES FOR TREATMENT OUTCOMES IN SYSTEMIC LUPUS ERYTHMATOSUS (2016) (0)
Is the number of TACE treatments in HCC patients associated with improved survival? A SEER-Medicare population analysis. (2012) (0)
Prevalence of first and subsequent skeletal-related events (SREs) in U.S. elderly patients with metastatic prostate cancer (mPC). (2014) (0)
PMH39 COMPARATIVE ANALYSIS OF DISCONTINUATION HAZARD FOR ATYPICAL ANTIPSYCHOTICS (2006) (0)
Use of Bone-Modifying Agents Following Androgen Deprivation Therapy for Medicare Non-Metastatic Prostate Cancer Patients (2014) (0)
PCN163 HEALTHCARE RESOURCE UTILIZATION AND COUNTY-LEVEL DETERMINANTS OF FOLLICULAR LYMPHOMA STAGE AT DIAGNOSIS (2019) (0)
P-394: Assessment of the impact of valdecoxib on systolic blood pressure in clinial practice (2005) (0)
HE3 DIFFERENTIAL RACIAL AND ETHNIC DISPARITIES IN HEALTH EXPENDITURE AND SELF-PERCEIVED HEALTH STATUS IN THE UNITED STATES (2006) (0)
PCV134 READMISSIONS AFTER UNAUTHORIZED DISCHARGES IN THE CARDIOVASCULAR SETTING (2010) (0)
PNS206 CAN WE IMPROVE THE ESTIMATION OF CENSORED COST DATA USING RANDOM FORESTS? (2019) (0)
PMH13 ASSOCIATION OF MEDICATION PERSISTENCE AND HEALTH-CARE UTILIZATION IN HIGH-COST PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH DULOXETINE OR VENLAFAXINE XR (2010) (0)
Heterogeneity of Treatment Effect of Androgen Deprivation Therapy In Patients With Incident Metastatic Prostate Cancer (2015) (0)
PCV66 COSTS ASSOCIATED WITH DISCHARGES AGAINST MEDICAL ADVICE IN A CVD POPULATION (2010) (0)
Early Assessment Of The 10-Step Patient Engagement Framework For Patient-Centered Outcomes Research Studies: The First 3 Steps (2016) (0)
Association of individual low-income status and area deprivation with mortality in multiple myeloma. (2023) (0)
PMD13 A Framework for the Creation of Objective Performance Criteria Among Medical Devices: Reflections from Stakeholders (2021) (0)
PMH56 STARTING DOSE AND PERSISTENCE FOR ZIPRASIDONE USERS IN MEDICAID (2005) (0)
PCV1 Modern Methods of Delivering Adjuvant Radiotherapy Treatment and the Risk of Cardiac Injury in Breast Cancer (2012) (0)
AI4 Comparing Machine-Learning Methods for the Prediction of Major Adverse Limb Events and Mortality after a Percutaneous Intervention (2021) (0)
Health services utilization differences between patients with metastatic (M1) and nonmetastatic (M0) prostate cancer (PCa). (2013) (0)
MSR72 Collaborative, Multisectoral, and Multidisciplinary Approach to Enhance FDA One Health Initiative Communication Strategies (2022) (0)
PCN12 TIMING OF PHYSICIAN VISITS AND THE IMPACT ON SURVIVAL AMONG SEER-MEDICARE PATIENTS WITH STAGE IV PROSTATE CANCER (2009) (0)
RS3 THE COST-EFFECTIVENESS OF TIOTROPIUM VERSUS IPRATROPIUM IN A US VETERANS POPULATION DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2006) (0)
Time to follow-up and treatment in patients with newly diagnosed prostate cancer (PC) across clinical stages in an equal access health system. (2013) (0)
Payers’ views on Heterogeneity of treatment effect in Oncology (2015) (0)
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: A Report of the ISPOR Drug Cost Task Force - Part IV: Medicare, Medicaid and Other US Government Payers Perspectives (2008) (0)
Second- and third-line chemotherapy regimens in elderly Medicare stage IV colon cancer patients. (2012) (0)
MP78-04 ORAL AND INTRAVENOUS BISPHOSPHONATE USE FOLLOWING ANDROGEN DEPRIVATION THERAPY AMONG MEDICARE BENEFICIARIES WITH NON-METASTATIC PROSTATE CANCER (2014) (0)
PCV133 THE COST-EFFECTIVENESS OF GENOTYPING CYP2C19 TO GUIDE ANTIPLATELET THERAPY SELECTION (2010) (0)
Patterns of use of docetaxel in stage IV prostate cancer (PCa) patients in SEER-Medicare. (2010) (0)
Questionnaire to Assess the Relevance and Credibility of a Prospective Observational Study (2016) (0)
PMH8 SWITCHING & DISCONTINUATION OF SERTRALINE, PAROXETINE AND CITALOPRAM THERAPY (2004) (0)
MM7 Issues in Developing Economic Models for Managed Care: The Case of Osteoporosis Prevention (1998) (0)
CN4 - COMPARISON OF MACHINE LEARNING ALGORITHMS FOR THE PREDICTION OF MISSING CROSS-SECTIONAL COST DATA (2018) (0)
Receipt of Treatment for Depression Following Traumatic Brain Injury (2020) (0)
Eliciting Treatment Preferences in Low-Risk Thyroid Cancer through Experience-Driven Clinical Vignettes: A Stakeholder-Engaged Approach (2023) (0)
Treatment duration and survival time: Does only the last line matter? (2015) (0)
Modeling the Annual Cost of Postmenopausal Prevention Therapy Using Hormone Replacement Therapy, Raloxifene, and Alendronate: P-24. (1999) (0)
Advantages Of Bayesian Adaptive Trials For Comparative Effectiveness Research (CER): “RE-ADAPT”ING ALLHAT (2013) (0)
PDB13 PHARMACY AND MEDICAL RESOURCE UTILIZATION AMONG INITIAL METFORMIN AND THIAZOLIDINEDIONE PATIENTS (2004) (0)
PCV15 Social Networks Help Control Hypertension (2012) (0)
PIN14 HEALTH RESOURCE UTILIZATION IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS (2002) (0)
Major GI Events among Cox-2 Inhibitor, NSAID, and Aspirin Users: 728 (2005) (0)
WW13: CHALLENGES IN PERFORMING META ANALYSIS IN HEART FAILURE OUTCOMES RESEARCH (2001) (0)
A methodological comparison of mapping algorithms to obtain health utilities derived using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415. (2020) (0)
Operation PCOR: A Community Engagement Project Preparing Veterans as Full Partners in PTSD-Related Research (2021) (0)
Risk and cost of anthracycline-induced cardiotoxicity among breast cancer patients in the United States. (2009) (0)
(402) Conceptual model of societal burden of non-medical use of prescription opioids/analgesics among patients with chronic pain (2008) (0)
Table of Contents Examination of Data , Analytical Issues and Proposed Methods for Conducting Comparative Effectiveness Research Using “ Real-World Data ” (2011) (0)
Radiation oncologist visits and the effect on prostate cancer (PCa) survival among SEER-Medicare patients with stage IV disease. (2011) (0)
Eliciting Low-Risk Thyroid Cancer Treatment Preferences using Clinical Vignettes: A Pilot Study. (2023) (0)
PID1: ESTIMATES OF THE INDIRECT COSTS OF HIV AND AIDS IN THE UNITED KINGDOM (1999) (0)
MAIN OUTCOME MEASURES (1997) (0)
Longitudinal predictive ability of mapping algorithms: Secondary analysis of NRG Oncology/RTOG 0415. (2021) (0)
Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study (2015) (0)
PMH46 TREATMENT PERSISTENCE WITH DULOXETINE AND HEALTH CARE COSTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (2010) (0)
Understanding the experience of living with non-small cell lung cancer (NSCLC): A qualitative study. (2013) (0)
Patient Characteristics Associated with Use of Monoclonal Antibody Treatment in Women with Metastatic Breast Cancer: A Population-Based Analysis. (2009) (0)
HT4 PRAGMATIC CLINICAL TRIALS FOR DRUG APPROVAL: IS IT REALISTIC? (2010) (0)
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: A Report of the ISPOR Drug Cost Task Force - Part I: Issues & Recommendations (2008) (0)
Algorithm for identifying various second- and third-line chemotherapy regimens in elderly U.S. Medicare patients with metastatic colon cancer. (2013) (0)
Use of growth factors associated with docetaxel and paclitaxel in patients with early-stage breast cancer in a community oncology center. (2009) (0)
PIN19 PRESCRIBING DECISIONS IN A UTILITY MODEL (2002) (0)
PCV35: COMPARABILITY OF PUBLISHED STUDIES ON COST-EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY: DO THE RESULTS HELP THE DECISION-MAKING PROCESS? (2001) (0)
Abstracts of the ISPOR 18th Annual International Meeting Research. (2013) (0)
PNL11 AN ECONOMIC EVALUATION OFTRIPTAN PRODUCTS FOR MIGRAINE (2005) (0)
Predictors of second- and third-line chemotherapy receipt in stage IV colon cancer Medicare beneficiaries. (2013) (0)
Impact of patient sample on costs of events in pharmacoeconomic models (2008) (0)
Outcomes after endoscopic local excision of early-stage gastric adenocarcinoma in the United States. (2023) (0)
Health Plans' Strategies For Managing Outpatient Specialty (2006) (0)
1528 An economic evaluation of triptan products for migraine (2005) (0)
How do first-line treatment and other factors affect the receipt of second-line treatment for elderly metastatic colon cancer patients? (2013) (0)
Frequency of Second and Third Line Treatment Among Elderly Medicare Stage 4 Colon Cancer Patients (2012) (0)
PMC36 THE POPULATION IMPACT OF CHEMOTHERAPY IN LATE-STAGE PROSTATE CANCER: A SIMULATION STUDY USING TAX327 AND SEER-MEDICARE DATA (2009) (0)
PUK25 Role of Health Literacy on Kidney Transplant Patients Immunosuppressant Drugs Information Needs (2012) (0)
CE4 A Framework for Stakeholder Engagement in Comparative Effectiveness Research (2012) (0)
PMH1 METABOLIC SYNDROME AND SECOND GENERATION ANTIPSYCHOTICS UTILIZATION—IMPACT OF PSYCHIATRIC COMORBIDITY AND POLYPHARMACY (2010) (0)
PRS10 TREATMENT COSTS ASSOCIATED WITH COMMUNITY ACQUIRED PNEUMONIA BY COMMUNITY LEVEL OF ANTIMICROBIAL RESISTANCE (2007) (0)
PCN97 PHYSICIAN REFERRAL PATTERNS AMONG ELDERLY PATIENTS WITH STAGE IV PROSTATE CANCER (PCA): AN ANALYSIS USING SEERMEDICARE DATA (2009) (0)
Taxane Treatment in Women with Incident Stage IV Breast Cancer. (2009) (0)
CV2 CARDIOVASCULAR RISK OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS COMPARED TO OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS: AN OBSERVATIONAL STUDY OF A MEDICAID POPULATION (2004) (0)
VP02 Are Journal Editors A Barrier To Publication Of Real World Evidence? (2017) (0)
Characteristics of elderly metastatic prostate cancer (M1 PC) long-term survivors in the SEER Medicare database receiving androgen-deprivation therapy (ADT). (2016) (0)
Second and Third Line Chemotherapy Regimens in Elderly Medicare Stage 4 Colon Cancer Patients (2012) (0)
Conceptual Model of Shared Decision Making and Patient Engagement in Neurology (P1.358) (2016) (0)
Incidence of diagnosed VTE among elderly Americans in the year following stage III or IV colon cancer diagnosis. (2010) (0)
WH1 BREAST CANCER PATIENTS' PREFERENCES FOR LOCAL AND SYSTEMIC THERAPY (2007) (0)
Comparative effectiveness and survival benefit of various treatment modalities in HCC: A SEER-Medicare analysis. (2013) (0)
Age at diagnosis and treatment for prostate cancer (PC) in two distinct integrated health care systems. (2013) (0)
Oxaliplatin- or irinotecan-based combination therapy versus 5-fluorouracil/leucovorin alone in the treatment of advanced colon cancer patients age 66 and older: An analysis using SEER-Medicare data. (2010) (0)
A Dynamic Approach for Budget Impact Analysis (BIA) in Oncology: Nonmetastatic Castration-Resistant Prostate Cancer (NMCRPC) as an Illustrative Example (2018) (0)
DIABETES DIABETES CONTROL THROUGH AN EDUCATIONAL INTERVENTION (2014) (0)
MP78-02 CUMULATIVE INCIDENCE OF SKELETAL RELATED EVENTS IN MEN WITH METASTATIC PROSTATE CANCER BASED ON ALTERNATIVE ALGORITHMS (2014) (0)
PMH77 ANTIPSYCHOTIC METABOLIC PROPENSITY AND POLYTHERAPY: INFLUENCE ON HOSPITALIZATION (2008) (0)
Association Between Overall Incremental Cost And Survival Benefit Of Second Line Chemotherapy/Biologics Treatment Among Elderly Medicare Metastatic Colon Cancer Patients (2013) (0)
PHPI9 MEDICATION NEEDS OF ELDERLY INDIVIDUALS WITHOUT PRESCRIPTION DRUG COVERAGE (2005) (0)
PCV21 ANTIHYPERTENSIVE DRUG BUDGET IMPACT OF THE ANGIOTENSIN II RECEPTOR BLOCKERS (ARB) IN THE UK (2006) (0)
PMH79 PHYSICAL MORBIDITY AMONG PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OFTHE NATIONAL HOSPITAL DISCHARGE REGISTRY (2010) (0)
Development of effectiveness guidance documents (EGDs) as a stakeholder-driven process for informing study designs for comparative effectiveness research (CER). (2011) (0)
DB2: INCOME DISPARITY IN DIFFUSION OF ORAL DIABETES THERAPY 1999-2001 (2003) (0)
Cost-effectiveness analysis of treatment modalities for hepatocellular carcinoma in the SEER-Medicare population. (2012) (0)
Reply to F. Perrone et al (2012) (0)
Multidisciplinary physician care and mortality in hepatocellular carcinoma (2013) (0)
Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. (2022) (0)
The impact of time of medical oncologist visit on survival among elderly patients with stage IV prostate cancer: An analysis using SEER-Medicare data. (2016) (0)
Increases in Marylanders' out-of-pocket drug spending outpaced overall drug spending in 2001 by fifteen percentage points. (2004) (0)
ND3 PRESCRIBING PATTERNS AMONG DEMENTIA PATIENTS AT THE VETERANS AFFAIRS MARYLAND HEALTH CARE SYSTEM (VAMHCS) (2009) (0)
CV3 MULTI-COUNTRY COMPARISON OF HYPERTENSION COSTS FROM HOSPITALIZATIONS AND AMBULATORY CARE (2002) (0)
Review of cost–effectiveness studies of pegylated therapies for hepatitis C (2005) (0)
The cost-effectiveness of transarterial chemoembolization treatments. (2012) (0)
Linezolid vs. Vancomycin: Re-hospitalization Rates among Patients with Pneumonia, Staphylococcal Infection, and Skin and Soft Tissue Infection (2009) (0)
HP2 TRENDS IN ANGIOTENSIN II RECEPTOR BLOCKER (ARB) PRESCRIBING AMONG GENERAL PRACTITIONERS IN THE UK (2006) (0)
PAR18 RACIAL DISPARITIES IN PRESCRIBING OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS OVER OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS IN A MEDICAID MANAGED CARE POPULATION (2004) (0)
Common head and neck cancer treatment pathways and associated costs in the U.S. commercial managed care population. (2009) (0)
PDG1 Comparative Effectiveness and Safety of Pharmaceuticals Assessed in Observational Studies Compared with Randomized Controlled Trials (2020) (0)
DB4 HEART FAILURE RISK OFTHIAZOLIDINEDIONES INA MEDICAID MANAGED CARE POPULATION (2005) (0)
Skeletal-related events (SREs), baseline comorbidity, and survival among elderly patients (pts) with metastatic (M1) prostate cancer (PCa) in SEER-Medicare. (2013) (0)
The effects of age, stage, treatment, and Charlson comorbidity index (CCI) on quality of life after prostate cancer diagnosis in a single cohort. (2013) (0)
PCN146 Specialty Care and Treatment in Medicare HCC Patients (2012) (0)
Skeletal-related events (SREs) and survival among elderly patients with stage IV prostate cancer (PCa) in SEER Medicare data. (2014) (0)
PCV31: ECONOMIC IMPACT OF UNCONTROLLED HYPERTENSION AMONG NSAID USERS (2003) (0)
780 DIFFERENCES IN PROVIDER ENCOUNTERS BETWEEN METASTATIC (M1) AND NON-METASTATIC (M0) PROSTATE CANCER (PCA) PATIENTS (2013) (0)
Chemotherapy Treatment and Survival in Estrogen Receptor Negative Metastatic Breast Cancer: A Population-Based Analysis. (2009) (0)
Effect of VTE on mortality in patients with stage III colon cancer. (2011) (0)
An Approach to Identify Delivery of Palliative Radiation Therapy Using Health Care Claims Data: A Proof-of-Concept Application of a Visual Analytics Tool. (2018) (0)
Costs Of End-Of-Life Treatments Among Elderly Metastatic Colon Cancer Patients (2016) (0)
PCN40 DISPARITIES IN MEDICAID CANCER EXPENDITURES (2004) (0)
Quality-of-care data from managed-care organizations. (1997) (0)
PHP36 HEALTH ECONOMICS DATA: USE AND PERCEIVED VALUE IN U.S. PAYERS' FORMULARY DECISIONS (2009) (0)
All products can't be the best, can they (2006) (0)
Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study. (2019) (0)
Subgroup analysis versus post-hoc analysis. (2001) (0)
Providing Patients with Cost Information (2015) (0)
Supporting the validity of outcomes research. (2004) (0)
COST-OF-ILLNESS STUDIES: CONSIDERATIONS WHEN DESIGNING COI RESEARCH (2016) (0)
An invitation to the health policy debates. (2008) (0)
Implementing stakeholder engagement to explore alternative models of consent: An example from the PREP-IT trials (2021) (0)
Quality versus Cost (2015) (0)
Pharmaceutical prices and policy (2004) (0)
Appropriate methodologies for assessing the quality of treatment and the conduct of outcomes research (2006) (0)
The advent of a Patient-Centered Outcomes Research Institute (2010) (0)
Innovations to the Management of Multiple Myeloma in the Managed Care Setting (2012) (0)
Additional file 1: of Understanding preferences for type 2 diabetes mellitus self-management support through a patient-centered approach: a 2-phase mixed-methods study (2016) (0)
Modeling the Budgetary Impact of Payer Utilization Management Strategies: An Adapted Framework Based on Lessons Learned. (2019) (0)
The complexity of assessing outcomes of combination therapy. (2003) (0)
Pharmaceutical use and outcomes in children. (2009) (0)
Expanding the learning health system model to be health literate (2022) (0)
Developing a Guide on How to Involve Patients in Research Studies (2020) (0)
Editorial comment. (2008) (0)
Additional file 2: of Understanding preferences for type 2 diabetes mellitus self-management support through a patient-centered approach: a 2-phase mixed-methods study (2016) (0)
Hidden Cost of Treatment: Side Effects (2015) (0)
Benefits Improvement and Protection Act’s Impact on Transplantation Rates Among Elderly MEDICARE Beneficiaries With End-Stage Renal Disease (2013) (0)
Toward Accountable Care: Achieving Value and Integration viaPopulation Health Management (2017) (0)
A welcome debate on statistical analysis. (2001) (0)
PNS245 DEVELOPING PRIORITIES FOR THE COMMUNITY ENGAGEMENT TRAINING OF HEALTHCARE PROFESSIONAL STUDENTS (2019) (0)
Models for Sustaining and Expanding Patient Involvement in PCOR (2014) (0)
Patient-reported outcomes: D j Vu? (2004) (0)
Borrowing from other disciplines. (2001) (0)
Affordability + Clinical Effectiveness = The Value Equation (2015) (0)
Endpoints in Pain: the Suitability for Health Economic Evaluation of Endpoint Designs in Chronic Pain Studies. (2014) (0)
Comorbidity Burden And Incremental Cost of Fractures In Medicare Men With Non-Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy (2015) (0)
AMCP Weighs in on Cost-Effectiveness (2015) (0)
The importance of motivating junior scholars (2007) (0)
Expanding the scope and level of evidence in evidence-based medicine (2003) (0)
Drug discounts for the uninsured. (2003) (0)
The economics of lipid management. (2001) (0)
Persistency measurement and cost-effectiveness analysis (2002) (0)
CKD Progression and Economic Burden in Individuals With CKD Associated With Type 2 Diabetes (2022) (0)
Pharmacoeconomics of NSAIDs: Beyond Bleeds (2015) (0)
The Use of Cost Effectiveness Analyses by PharmaceuticalBenefit Managers (1995) (0)
New Conversations About Costs of Cancer Care (2015) (0)
Information is a good thing (2006) (0)
Using databases to optimize health care and outcomes research (2004) (0)
Managing work flow in high enrolling trials: The development and implementation of a sampling strategy in the PREPARE trial (2021) (0)
Finding Value in Healthcare (2015) (0)
PROFILE OF OLDER PUBLIC TRANSPORTATION USERS IN THE UNITED STATES: IMPLICATIONS FOR AGE-FRIENDLY COMMUNITIES (2022) (0)
Joining Forces with Veterans: Veterans’ and Researchers’ Perspectives on Veteran-Centered Engagement Practices (2023) (0)
Shining Light and Creating Solutions: Health and Social Needs of Older Affordable Housing Residents (2020) (0)
Attitudes Toward a Pre-authorized Concealed Opioid Taper: A Qualitative Analysis of Patient and Clinician Perspectives (2022) (0)
Qualitative inquiry from multiple perspectives of barriers and facilitators of oral health care for adults with disabilities. (2022) (0)
Creation of objective performance criteria among medical devices (2022) (0)
Moving Beyond "Leaning In"-It Is Time to Reach Out and Partner to Solve the Military Sleep Problem. (2021) (0)
Archaeology for the People: Community-Based Research, Hands-On Education, and their Place in Archaeology (2019) (0)
Constructing Health State Descriptions for Low-Risk Thyroid Cancer: Stakeholder Engagement and Formative Qualitative Research (2022) (0)
Ability of Caprini and Padua Risk-Assessment Models to Predict Venous Thromboembolism in a Nationwide Study (2023) (0)
Effects in Anemia Management of Dialysis Patients (2007) (0)
Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis (2022) (0)
Longitudinal Study of Prevalence of Sodium Abnormalities in Hospitalized Patients With COVID-19 (2021) (0)
Abnormal Sodium is a Predictor for Respiratory Failure and Mortality in Hospitalized Patients With COVID-19 (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With C. Daniel Mullins?

C. Daniel Mullins is affiliated with the following schools:

University of Maryland, College Park
Rutgers University
University of Maryland, Baltimore
University System of Maryland
Johns Hopkins University
University of California, San Francisco